Traws Pharma, Inc.
No SEC Form 4 filings for $TRAW in the last 30 days.
See all $TRAW insider activity →Traws Pharma (TRAW) agreed to a $50M stock purchase facility with Roth Principal Investments, allowing the sale of newly issued shares over 36 months. Proceeds will support product development and corporate purposes. A related agreement requires TRAW to file a registration statement for resale of these shares.
Traws Pharma, Inc. (TRAW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 23, 2026, Traws Pharma, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as
Traws Pharma (NASDAQ:TRAW) shares rose 3.9% in pre-market trading after reporting a narrower-than-expected Q2 loss of $0.16 per share, beating estimates of $0.43. The company had no revenue, down from $2.7M in Q2 2025 due to a one-off licensing item. Traws aims to resubmit tivoxavir marboxil to regulators in Q3 2026 and resolve an FDA clinical hold by year-end. Cash runway extends into early 2027.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TRAW (Traws Pharma, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent TRAW coverage spans corporate actions, market movers and earnings.
The facility allows Traws to issue up to $50 M of new shares over 36 months, potentially diluting existing shareholders but providing capital for product development.
The financing option may provide cash but also dilutes existing shareholders, likely creating short‑term price pressure.
The stock reaction is tied to better-than-expected loss plus clearer regulatory milestones for tivoxavir marboxil, but revenue remains zero and FDA clinical hold is still unresolved.
Near-term catalyst is regulatory progress on the MHRA resubmission and potential resolution of the FDA clinical hold, alongside milestone-linked financing optionality.
The 8-K discloses equity-plan share authorization and related governance outcomes, which can affect dilution expectations and near-term sentiment.
AlphAI scores every news story that mentions TRAW with an AI model for sentiment and relevance, and aggregates insider trades from Traws Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Traws Pharma (TRAW) agreed to a $50M stock purchase facility with Roth Principal Investments, allowing the sale of newly issued shares over 36 months. Proceeds will support product development and corporate purposes. A related agreement requires TRAW to file a registration statement for resale of these shares.
1 min readTraws Pharma, Inc. (TRAW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 23, 2026, Traws Pharma, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as
1 min readTraws Pharma (NASDAQ:TRAW) shares rose 3.9% in pre-market trading after reporting a narrower-than-expected Q2 loss of $0.16 per share, beating estimates of $0.43. The company had no revenue, down from $2.7M in Q2 2025 due to a one-off licensing item. Traws aims to resubmit tivoxavir marboxil to regulators in Q3 2026 and resolve an FDA clinical hold by year-end. Cash runway extends into early 2027.
5 min readTraws Pharma, Inc. (TRAW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights · Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study · Completed the
6 min readTraws Pharma, Inc. (TRAW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001130598 0001130598 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report
4 min readTraws Pharma (TRAW) has announced a 15-day delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company attributes this delay to recurring operating losses, ongoing efforts to secure financing to meet Nasdaq listing requirements, and the need for KPMG LLP to complete audit procedures following management's going-concern assessment. Despite the delay, Traws Pharma provided preliminary financial results for 2025, projecting $2.8 million in revenue and a net income of approximately $9.2 million.
3 min read
